Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database ; volume:14 ; number:1 ; day:23 ; month:8 ; year:2024 ; pages:1-11 ; date:12.2024
Scientific reports ; 14, Heft 1 (23.8.2024), 1-11, 12.2024
- Urheber
-
Kim, Hyo Jung
Yoon, Jeong-Hwa
Park, Yeon Hee
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-69614-x
- URN
-
urn:nbn:de:101:1-2411120902050.534656588812
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Hyo Jung
- Yoon, Jeong-Hwa
- Park, Yeon Hee
- SpringerLink (Online service)
Ähnliche Objekte (12)
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database